Elucidating the Mechanism of Regulation of Transforming Growth Factor β Type II Receptor Expression in Human Lung Cancer Cell Lines  by Halder, Sunil K. et al.
Elucidating the Mechanism of
Regulation of Transforming
Growth Factor β Type II
Receptor Expression in Human
Lung Cancer Cell Lines1,2
Sunil K. Halder*, Yong-Jig Cho*,†, Arunima Datta*,
Govindaraj Anumanthan‡, Amy-Joan L. Ham§,
David P. Carbone¶,# and Pran K. Datta*,†,#
*Department of Surgery, Vanderbilt University School of
Medicine, Nashville, TN, USA; †Department of Veterans
Affairs Medical Center, Nashville, TN, USA; ‡Department of
Urologic Surgery, Vanderbilt University School of Medicine,
Nashville, TN, USA; §Department of Biochemistry,
Vanderbilt University School of Medicine, Nashville, TN,
USA; ¶Department of Medicine, Vanderbilt University
School of Medicine, Nashville, TN, USA; #Vanderbilt-Ingram
Cancer Center, Vanderbilt University School of Medicine,
Nashville, TN, USA
Abstract
Lung carcinogenesis in humans involves an accumulation of genetic and epigenetic changes that lead to alterations
in normal lung epithelium, to in situ carcinoma, and finally to invasive and metastatic cancers. The loss of transform-
ing growth factor β (TGF-β)–induced tumor suppressor function in tumors plays a pivotal role in this process, and
our previous studies have shown that resistance to TGF-β in lung cancers occurs mostly through the loss of TGF-β
type II receptor expression (TβRII). However, little is known about the mechanism of down-regulation of TβRII and
how histone deacetylase (HDAC) inhibitors (HDIs) can restore TGF-β–induced tumor suppressor function. Here we
show that HDIs restore TβRII expression and that DNA hypermethylation has no effect on TβRII promoter activity in
lung cancer cell lines. TGF-β–induced tumor suppressor function is restored by HDIs in lung cancer cell lines that
lack TβRII expression. Activation of mitogen-activated protein kinase/extracellular signal–regulated kinase pathway
by either activated Ras or epidermal growth factor signaling is involved in the down-regulation of TβRII through
histone deacetylation. We have immunoprecipitated the protein complexes by biotinylated oligonucleotides
corresponding to the HDI-responsive element in the TβRII promoter (−127/−75) and identified the proteins/factors
using proteomics studies. The transcriptional repressor Meis1/2 is involved in repressing the TβRII promoter activity,
possibly through its recruitment by Sp1 and NF-YA to the promoter. These results suggest amechanism for the down-
regulation of TβRII in lung cancer and that TGF-β tumor suppressor functions may be restored by HDIs in lung cancer
patients with the loss of TβRII expression.
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Introduction
Lung carcinogenesis involves an accumulation of genetic and epige-
netic changes leading to functional inactivation of tumor suppressor
genes and activation or up-regulation of cellular oncogenes. The loss
of transforming growth factor β (TGF-β)–induced tumor suppressor
function in tumors is believed to play a pivotal role in this process.
The unresponsiveness to TGF-β could be caused by multiple ways
involving both genetic and epigenetic alterations of TGF-β type II
receptor expression (TβRII). Mutations within the coding sequence
of the TβRII gene are rare in non–small cell lung cancer (NSCLC).
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Mutations in Smad2 and Smad4 genes have been found in 5% to
10% of lung cancers [1,2]. Osada et al. [3] showed that 29 of 33
lung cancer cell lines are unresponsive to TGF-β–induced growth in-
hibition [4]. TβRII expression was shown to be decreased in 80% of
squamous cell carcinoma, 42% adenocarcinoma, and 71% large cell
carcinoma [5]. We have shown that the stable expression of TβRII in
TGF-β–unresponsive cells restores TGF-β–induced inhibition of cell
proliferation, induction in apoptosis, and decrease in tumorigenicity.
These findings suggest that cancer cells could result in escape from the
autocrine growth-inhibitory effect of TGF-β due to the loss of expres-
sion of TβRII [5]. The TβRII promoter has four major regulatory
elements: two positive (PRE1 and PRE2) and two negative regulatory
elements (NRE1 and NRE2) [6]. Sp1 binds to the TβRII promoter at
positions −102 and −59, whereas an inverted CCAAT box in NRE2
at position −83 was identified as NF-Y protein binding site [7,8]. The
ets family gene, FLI1, fused with the Ewing sarcoma EWSR1 gene
(EWSR1-FLI1) binds to TβRII promoter and suppresses the expres-
sion of TβRII [9].
Abnormal histone deacetylase (HDAC) activity and histone acetyl
transferase activity in cancers play a major role in deregulating tumor
suppressor and tumor promoter genes. HDACs modify histones
through deacetylation leading to alterations in chromatin structure.
Alteration of HDAC activity is central to the control of cell prolifera-
tion by the Myc/Mad and Rb/E2F pathways. The cell cycle regulatory
proteins p21Cip1, p16INK4A, and cyclins A and D are regulated by sev-
eral HDAC inhibitors (HDIs) [10,11]. The HDIs are potent inducers
of apoptosis depending on cell types [12]. Trichostatin A (TSA) in-
hibits hypoxia-induced angiogenesis through reactivation of p53 and
VHL and concurrent suppression of hypoxia-inducible factor 1α and
vascular endothelial growth factor [13]. The antitumor activity of the
HDI, MS-275, has been reported in in vitro studies and xenograft
studies using human tumor cell line [14–16].
Little is known about the mechanism by which the expression
TβRII goes down and how TGF-β–mediated antitumor activity
can be restored by HDIs in lung cancer. In this study, we demonstrate
that TβRII expression is restored by HDIs in lung cancer cell lines
lacking TβRII, and activation of mitogen-activated protein kinase
(MAPK)/extracellular signal–regulated kinase (ERK) pathway is im-
portant in the down-regulation of TβRII. Using proteomics studies
and DNA affinity precipitation assay (DAPA), we have identified a
number of factors that are involved in the regulation of TβRII. We
have observed that Meis2 represses TβRII promoter activity through
binding with Sp1 and NF-Y. Taken together, our results suggest a
mechanism for the down-regulation of TβRII and restoration of
TGF-β signaling in lung cancer cells.
Materials and Methods
Cell Lines
A549, VMRC-LCD, and ACC-LC-176 cell lines were maintained
in RPMI supplemented with 10% fetal bovine serum (FBS). Activated
Ras expressing RIE–inducible Ras (iRas) cells were maintained in
Dulbecco modified Eagle medium containing 10% FBS with 150 μg/ml
hygromycin B and 200 μg/ml G418.
Reagents and Antibodies
Reagents were purchased as follows: TGF-β1 from R&D Systems
(Minneapolis, MN); PD98059, U0126, and anti–Pan Ras from
Calbiochem (San Diego, CA); and isopropylthio-β-galactoside
(IPTG), 5-aza-2-deoxycytidine (AZA), and TSA from Sigma Bio-
chemicals (St Louis, MO). Antibodies were purchased as follows: anti–
phospho-ERK from Cell Signaling (Denver, MA); anti–acetylated
histone H3/H4 from Upstate Biotechnology (Waltham, MA); and
anti-p21Cip1, anti-Smad4, anti-TβRII, anti-ERK, anti-Sp1, anti–NF-YA,
and anti–MEIS-2 from Santa Cruz Biotechnology (Santa Cruz, CA).
Reverse Transcription–Polymerase Chain Reaction Analysis
VMRC-LCD, ACC-LC-176, and A549 cells were treated with
HDIs and/or DNA methylation inhibitor (AZA) for 24 hours. Total
RNA was isolated, and reverse transcription–polymerase chain reaction
(RT-PCR) analysis for amplification of human TβRII gene fragment
(493 base pair) was performed as described previously [5].
Expression Plasmids for NF-YA and Meis2 and TβRII
HDI-Responsive Element Promoter Constructs
RT-PCR analyses were performed using primers 5′-AAGCTTAC-
CATGGAGCAGTATACAGCA-3′ (forward) and 5′-GTCGACG-
GACACTCGGATGATCTGTGT-3′ (reverse) to amplify the coding
region of NF-YA gene and primers 5′-AATATAAGCTTGGGATG-
GACGGAGTAGGGGTTC-3′ (forward) and (5′-CTGACCTC-
GAGCATGTAGTGCCATTGCCCATCC-3′) (reverse) for the
Meis2 gene. RT-PCR products were cloned into pcDNA3-HA vector.
To determine the role of the HDI-responsive element (HRE) on TβRII
promoter activity and inducibility, the −115/−64 region of TβRII pro-
moter was subcloned into pGL3 basic vector using a set of specific for-
ward and reverse oligo primers (Figure W3) to generate a wild-type
(WT) HRE, Sp1 site mutant, NF-YA site mutant, and both Sp1 and
NF-YA site mutant constructs.
Transcriptional Response Assay
VMRC-LCD cells were cotransfected with CMV-β-gal and p3TP-
Lux or (CAGA)9 MLP-Luc plasmids together with other expression
plasmids. Cells were incubated with 5 ng/ml of TGF-β1 with TSA
(250 nM) in 0.2% FBS for 22 hours. ACC-LC-176 cells were
cotransfected with TβRII promoter luciferase constructs and CMV-
β-gal. Transfected cells were treated with TSA (250 nM), MS-275
(500 nM), and/or AZA (1 μM) for 22 hours, and luciferase activities
were measured as described previously [17].
Western Blot Analyses
RIE-iRas cells were treated with 5 mM IPTG in the presence of
TSA (250 nM). RIE-iRas cells were also treated with 5 nM IPTG in the
presence of TSA, PD98059, or U0126. RIE cells were serum starved
and treated with epidermal growth factor (EGF) in the presence of TSA
or U0126 for 24 and 48 hours. Preparation of cell lysates and Western
blot analyses were performed as described previously [17].
[3H]thymidine Incorporation Assay
A549 (15,000 cells/well) and VMRC-LCD (30,000 cells/well)
cells were treated with increasing doses of TSA in the presence of
10% FBS/medium for 44 hours. VMRC-LCD cells were also treated
with TSA in the presence of SB-431542 (5 μM). [3H]thymidine
(4 μCi/well) was added in each well for an additional 4 hours, and cells
were then processed for thymidine incorporation assay as described
previously [18].
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Figure 1. Restoration of TGF-β–induced tumor suppressor functions by TSA. (A) VMRC-LCD cells were transiently cotransfected with
CMV-β-gal, p3TP-Lux or (CAGA)9 MLP-Luc plasmids, together with the indicated expression plasmids. Cells were treated with TGF-β
alone or both TGF-β and TSA. Normalized luciferase activity was expressed as the mean ± SD of triplicate measurements. *P < .05
compared with the corresponding control. **P < .05 when compared between the two data points. ***P < .05 when compared with
the corresponding control. (B) Thymidine incorporation assay: A549 and VMRC-LCD cells were treated with increasing amounts of TSA
(left). VMRC-LCD cells were also treated with increasing doses of TSA in the presence or absence of SB-431542 (SB) (right). Radioac-
tivity incorporated without TSA treatment is considered as 100%, and the results are expressed as the mean ± SD. *P < .05 compared
with the corresponding control. ΔP < .05 and ΔΔP < .05 compared with the corresponding SB treatment. (C) Soft agarose assay was
performed as described in Materials and Methods. In addition, 5 × 103 ACC-LC-176 cells were plated on soft agar as described above
except that TSA and/or SB-431542 were added on the top agar layer every third day. Each data point represents the number of colonies
from an average of three values. *P < .05 compared with the corresponding control. **P < .05 when compared between the two data
points. (D) In vivo tumorigenicity assay: ACC-LC-176, VMRC-LCD, and A549 were injected subcutaneously behind the anterior fore limb
of BALB/c athymic nude mice. TSA (25 μg/d per mice) was administered intraperitoneally. Growth curves are plotted from the mean
volume ± SD of tumors from six mice in each group. *P < .05 compared with the corresponding control.
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Soft Agarose Assay and Xenograft Studies
A total of 15 × 103 cells (A549 or VMRC-LCD) were plated for soft
agarose assay as described before [17]. TSA and/or SB-431542 (5 μM)
were added on the top agar layer every third day, and after 10 days,
colonies were counted. Each data point is a representative of an average
of three independent values. ACC-LC-176, VMRC-LCD, and A549
cells (4 × 106) were injected subcutaneously in BALB/c athymic nude
mice. TSA was administered by intraperitoneal injection everyday until
sacrifice. Tumor volumes were measured as before.
DNA Affinity Precipitation Assay
The single-stranded 5′-biotinylated oligonucleotides corresponding
to the TβRII promoter region (−127/−65, WT oligos) and the mutant
sequence (MT oligos, mutated Sp1, and NF-Y binding sites) were
purified, annealed, and then used for DAPA as described [19]. Briefly,
1.5 μg of biotin end-labeled double-strand oligonucleotides was incu-
bated with 1 mg of nuclear extracts from untreated or TSA-treated
ACC-LC-176 cells in DAPA buffer on ice for 1 hour. The DNA-
protein complexes were precipitated with 50 μl of streptavidin-agarose
beads, and complexed proteins were detected byWestern blot analyses.
Proteomics Analyses
The DAPA experiments were performed with a larger amount of
nuclear extracts (∼2.0 mg) from ACC-LC-176 cells. DNA-protein
complexes were precipitated and resolved in a 10% SDS-PAGE. Pro-
tein regions in each lane were cut, digested in-gel by trypsin or chymo-
trypsin, extracted, and analyzed by liquid chromatography–tandem
mass spectrometry (LC-MS/MS) using an LTQ ion trap mass spec-
trometer (ThermoFisher, San Jose, CA) at the Vanderbilt University
Proteomics Laboratory. The MS/MS analysis of the peptides was per-
formed using data-dependent scanning in which one full MS spectrum
was followed by three MS/MS spectra. The data were searched with the
Myrimatch algorithm (v1.6.75) [20] using a human database created from
the UniProtKB database (v155). The data were filtered with the IDPicker
algorithm (v2.6.165.1) [21,22] using a 5% false discovery rate (FDR)
(determined using reverse sequence hits), requiring at least two unique
peptides per protein and parsimonious analysis to report a minimal list
of proteins. A more detailed description of LC-MS/MS methods can be
obtained on request. Specific proteins were further verified by DAPA.
Statistical Analysis
All statistical analyses were performed using paired t test. The
paired t test was used to assess the significance of differences in vehicle
control and treated data points. Values were considered to be statisti-
cally significant when P < .05.
Results
HDIs Restore TGF-β–Mediated Tumor Suppressor Function
by Inducing TβRII Expression
To determine whether reduced expression of the TβRII gene is
responsible for blocking TGF-β signals in VMRC-LCD cells, we used
two TGF-β–responsive reporters, p3TP-Lux and (CAGA)9 MLP-Luc
(Figure 1A). Both reporters were induced by TGF-β in the presence of
TSA but not in the absence of TSA (Figure 1A). Dominant-negative
type II receptor (DN-RII) blocked TGF-β–induced reporter activity
in the presence of TSA, and constitutively active type I receptor (Act-RI)
activated the transcriptional responses in the absence of TSA and TGF-β,
suggesting that this cell line has intact TGF-β/Smad signaling downstream
of TβRII and that the HDIs can restore TGF-β signaling in the cells lack-
ing TβRII expression. We also observed similar restoration of TGF-β sig-
naling by HDIs in the ACC-LC-176 cell line lacking TβRII expression
(data not shown). To test how VMRC-LCD cells (with down-regulation
of TβRII) and A549 cells (with functional TβRII) respond toTSA-induced
growth arrest, [3H]thymidine incorporation assay was performed. VMRC-
LCD cells show stronger inhibition of thymidine incorporation by TSA
than that of A549 cells (Figure 1B, left panel ). To determine whether
TSA uses endogenous TGF-β signaling to inhibit growth, we performed
thymidine incorporation assay after treating cells with either TGF-β alone
or TSA in the presence of SB-431542, an inhibitor of TGF-β signaling
Figure 2. The HDIs restore TβRII expression in VMRC-LCD (A) and ACC-LC-176 (B) cells but not in A549 (C) cells. Human lung tumor cell
lines, VMRC-LCD, ACC-LC-176 (without TβRII expression), and A549 (with TβRII expression), were treated with HDIs and AZA. RT-PCR
analyses for TβRII gene expression were performed with total RNA as described previously [5].
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(Figure 2B, right panel ). TGF-β had no effect on thymidine incorporation
in this cell line. Treatment of cells with TSA decreased the thymidine
incorporation in a dose-dependent manner, which was partially blocked
by SB-431542, suggesting that restoration of endogenous TGF-β signaling
by TSA is required for its full growth inhibition effects. We next tested
in vitro whether TSA can reduce tumorigenicity of A549 cells that have
intact TGF-β signaling and VMRC-LCD cells that lack TβRII expression
(Figure 1C, left panel ). We have observed that TSA reduces colony forma-
tion by only 10-fold in A549 cells, whereas a 91-fold reduction in colony
formation is observed in VMRC-LCD cells. To determine whether endog-
enous TGF-β signaling is involved in the antitumor effects of theHDIs, we
performed soft agar assay using ACC-LC-176 cells lacking TβRII
(Figure 1C, right panel ). Treatment with TSA reduces the colony numbers
and SB-431542 partially blocks the effects of TSA on reducing colony for-
mation. To test this in vivo, we performed xenograft formation studies with
(A549) or without (ACC-LC-176 and VMRC-LCD) TβRII expression
Figure 3. TSA treatment restores Ras- and EGF-mediated down-regulation of TβRII expression. (A) Lysates from RIE-iRas cells treated
with 5 mM IPTG were analyzed by Western blots using anti-TβRII and anti–Pan-Ras antibodies. (B) Lysates from RIE-iRas cells treated
with IPTG in the presence or absence of TSA for indicated times were analyzed by Western blots using anti-TβRII, anti–Ac-histone-H3,
anti–Ac-histone-H4, and anti-β–actin antibodies. (C) Lysates from RIE-iRas cells treated with IPTG in the presence of TSA, PD98059, or
U0126 for 24 and 48 hours were analyzed by Western blot analyses. (D) Lysates from parental RIE cells treated with EGF (10 ng/ml) in
the presence of TSA or U0126 for 24 and 48 hours were analyzed by Western blots.
Figure 4. The promoter region of TβRII (−127/−75) is required for its induction by MS-275 and TSA. (A) A schematic diagram represent-
ing the multiple regulatory elements within the TβRII promoter. The TβRII promoter luciferase constructs and β-gal plasmid were tran-
siently cotransfected into ACC-LC-176 cells. Transfected cells were treated with TSA, MS-275, and/or AZA (B). Luciferase activity was
normalized and expressed as the mean ± SD. *P < .05 and **P < .05 compared with the corresponding control.
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Figure 5. Identification of proteins that bind to HRE of TβRII promoter. (A) The WT and mutated (Sp1 and NF-YA sites mutated) oligo-
nucleotide sequences containing HRE in the TβRII promoter are shown. (B) An EMSAwas performed using 32P-labeledWT oligo (−115/−64
of TβRII promoter, WO) and mutant oligo probes by incubating nuclear lysates from A549 and ACC-LC-176 cells. In competitive binding or
supershift assays, unlabeled WO or MO or antibodies against Sp1 or NF-Y was preincubated with the nuclear extract. DNA-protein com-
plexes were resolved in a 5% native acrylamide gel. (C) Biotinylated double-stranded oligo corresponding to the −127/−65 sequence
(WT oligo) or mutant oligo (MT oligo) was mixed with equal amounts of nuclear extracts prepared from ACC-LC-176 cells treated with
TSA or MS-275. DNA-protein complexes were precipitated with streptavidin-agarose beads and subjected to Western blot analyses for
Sp1, NF-YA, andMeis2. (D) DAPAwas performed usingWT andmutant oligos for proteomics studies. DNA-protein complexeswere precip-
itated and resolved in 10% SDS-PAGE. Proteins were eluted, digested with trypsin or chymotrypsin, and finally analyzed by LC-MS/MS.
The number of unique peptides and the number of total spectra including two representative peptide sequences for each protein detected by
MS are shown.
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(Figure 1D). We observed stronger tumor regression by TSA in mice in-
jected with ACC-LC-176 (left panel ) or VMRC-LCD (middle panel ) cells
than that in mice injected with A549 cells (Figure 1D, right panel). Taken
together, our data suggest that HDIs can restore TGF-β–induced tumor
suppressor function through the induction of TβRII expression.
HDIs Restore TβRII Expression in VMRC-LCD and
ACC-LC-176 Cells
To determine whether HDIs, including MS-275, depsipeptide,
TSA, and sodiumbutyrate, and themethylation inhibitor AZA can induce
TβRII mRNA expression, we performed semiquantitative RT-PCR
analyses using lung tumor–derived VMRC-LCD and ACC-LC-176
cell lines without TβRII expression and A549 cell line with TβRII expres-
sion (Figure 2). Treatment with HDIs increases TβRII mRNA expression
in VMRC-LCD (Figure 2A) and ACC-LC-176 (Figure 2B) cells but not
in A549 cells (Figure 2C ). AZA has no effect on the TβRII promoter
activity alone or in combination with HDIs. These data suggest that
the HDIs induce TβRII mRNA expression in lung tumor cell lines that
lack TβRII expression, and DNA hypermethylation is not involved in
this process.
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Activation of the MAPK/ERK Pathway Is Involved in the
Down-regulation of TβRII through Histone Deacetylation
Activation of K-Ras [23] and up-regulation or activation of EGF re-
ceptor (EGFR) inNSCLC [24] is associated with the activation ofMEK/
ERK pathway. To examine the effect of oncogenic Ras on TβRII expres-
sion, we used inducible RIE-iRasV12 stable cell line where IPTG can
induce activated Ras expression. TβRII expression is downregulated in
a time-dependent manner with increasing levels of activated Ras expres-
sion (Figure 3A). In an attempt to determine whether oncogenic Ras-
mediated repression of TβRII expression is through histone deacetylation,
we observed that TβRII expression is restored by TSA that increases
the levels of acetylated histone H3 and H4 (Figure 3B). To determine
whether activation of MAPK/ERK pathway is involved in Ras-induced
down-regulation of TβRII, we performed Western blot analyses after
treating the cells with IPTG and either TSA, PD98059, or U0126
(Figure 3C). These inhibitors efficiently blocked Ras-mediated down-
regulation of TβRII. To examine whether EGF-induced activation of
MEK/ERK pathway can downregulate TβRII expression, RIE cells were
treated with EGF in the presence of TSA or U0126. EGF significantly
downregulates TβRII expression in these cells within 48 hours, and TSA
or U0126 can restore the TβRII expression (Figure 3D). These experi-
ments suggest that sustained activation of MAP/ERK pathway either
by activation of Ras or by EGF signaling causes down-regulation of
TβRII through the recruitment of HDAC activity.
TβRII Promoter Region (−127/−75) Is Required for Its
Activation by the HDIs, MS-275, and TSA
To determine whether increased expression of TβRII mRNA by the
HDIs is due to the activation of TβRII promoter, we performed tran-
sient transfection assays with serial deletion of 5′-promoter constructs
into ACC-LC-176 cells and then treated with MS-275, TSA, or AZA
(Figure 4A). The WT constructs show low basal activity, and either
MS-275 or TSA efficiently induced the promoter activity when the
−127/−75 region remains intact in the TβRII promoter constructs.
MS-275 is stronger than TSA in inducing TβRII promoter activity,
and AZA alone or in combination with MS-275 or TSA has no effect
(Figure 4B). Interestingly, the promoter region −127/−75 contains
Sp1 and NF-YA binding sites. Therefore, these results suggest that
the promoter region −127/−75 containing Sp1 and NF-YA binding
sites is required for MS-275– and TSA-mediated induction of
TβRII promoter.
Identification of Proteins Involved in the Regulation of TβRII
Expression Using Proteomics Studies
To determine whether Sp1 or NF-YA binds to the Sp1 site or in-
verted CCAAT box, respectively, in the HRE region (−127/−75, HRE),
we performed electrophoretic mobility shift assays (EMSA) using
nuclear extract from A549 and ACC-LC-176 cell lines (Figure 5B).
Sp1 and NF-YA bind to the WT probe but do not bind to the mutant
oligo (MO) probe. A cold competition with WT HRE completely
abolished the complexes, whereas competition with cold mutant oligo
has no effect, suggesting the specific binding of Sp1 and NF-YA to
HRE in TβRII promoter. This is confirmed by supershift assays using
Sp1 or NF-YA antibodies (Figure 5B). To get a better idea about the
identity of proteins involved in the down-regulation of TβRII and to
determine the factors involved in restoring TβRII expression by HDIs,
we performed proteomics studies after immunoprecipitating the com-
plex using biotinylated double-stranded oligonucleotides corresponding
to HRE. First, to test the specificity of binding and in immunopre-
cipitating the complex, biotinylated WT oligo corresponding to HRE
sequence or mutant sequence (mutated Sp1 and NF-YA binding sites;
Figure 5A) was incubated with precleared nuclear lysate, and DNA-
bound protein complexes were subjected to Western blot analyses
(DAPA). The WT oligonucleotide immunoprecipitated both Sp1 and
NF-YA, whereas the mutant oligonucleotide did not (Figure 5C , left
panel ). To test the effect of HDIs on DNA binding affinity, we per-
formed DAPA after treating cells with either MS-275 or TSA. We
observed that the HDIs increased binding of Sp1 and NF-YA to the
DNA, and there was no appreciable change in the amount of immuno-
precipitated Meis2 (identified by proteomics studies). For mass spectral
analyses, immunoprecipitated protein complexes were resolved by
SDS-PAGE, digested with trypsin or chymotrypsin and analyzed by
LC-MS/MS. The sequence of each peptide was confirmed by MS/MS
analyses, thus demonstrating the identity of immunoprecipitated pro-
teins (Figure 5D). The number of unique peptides and the number of
total spectra including two representative peptides for each protein de-
tected by LC-MS/MS are shown (Figure 5D). Thus, we successfully
identified a number of unique proteins that were precipitated by WT
HRE and not by the mutated oligonucleotide.
Figure 6. Meis2 inhibits HDI-induced TβRII promoter activity. (A) Vector control and Meis2-overexpressing ACC-LC-176 clones were
transiently cotransfected with CMV-β-gal and TβRII promoter reporter plasmids. Transfected cells were treated with MS-275, and the
normalized relative luciferase activities are shown. *P < .05 compared with the corresponding control. **P < .05 compared between
corresponding treatment points. (B) ACC-LC-176 cells were transiently cotransfected with CMV-β-gal and various plasmid constructs that
contain WT HRE, HRE (Sp1 mutant), HRE (NF-YA mutant), or HRE (double mutant). Transfected cells were treated with MS-275, and the
relative luciferase activities are shown. *P< .05 compared with the corresponding control. **P< .05 compared with the corresponding
WT treatment point. (C) ACC-LC-176 cells were transiently cotransfected with CMV-β-gal and various plasmid constructs as described
above. Transfected cells were treated with MS-275 with or without EGF (10 ng/ml), and the relative luciferase activities are shown. *P <
.05 compared with the corresponding control. **P< .05 compared with corresponding treatment points. ΔP< .05 when compared with
the WT treatment point. (D) Meis2 physically interacts with Sp1 and NF-YA. 293T cells were cotransfected with Meis2-HA and Sp1-Flag
(left) or Meis2-Flag and NF-YA-HA (right panel) expression vectors. Cell lysates were subjected to immunoprecipitation (IP) with anti-Flag
or anti-HA antibodies, and the presence of Meis2 in the complex was detected by Western blot analysis. Expressions of Meis2-HA,
Meis2-Flag, Sp1-Flag, and NF-YA-HA proteins were determined (bottom panels). (E) Hypothetical model for the loss of TGF-β tumor sup-
pressor function in lung cancer. Up-regulation/activation of EGF receptor (EGFR) and/or oncogenic activation of Ras in lung cancer result
in the activation of MEK/ERK pathway that leads to down-regulation of TβRII. MEK1/2 inhibitors block the down-regulation of TβRII in-
duced by activated Ras or EGFR. The reduced level of TβRII is due to the recruitment of HDAC activity on the promoter by transcription
factors (TF) with subsequent replacement of histone acetyl transferase proteins including p300 and CBP. TGF-β–induced tumor suppres-
sor function may be restored by treatment with HDIs in lung tumors that are resistant to TGF-β due to the loss of TβRII expression.
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Meis2 Represses Transcription through the Interaction
with Sp1 and NF-YA
The homeodomain transcriptional repressors, Meis1/Meis2, were
identified as coprecipitating proteins with the HRE oligonucleotide.
To test the role of Meis proteins in the regulation of TβRII promoter,
we have stably expressed Meis2 in ACC-LC-176 cell line (Figure W1).
We transfected TβRII promoter constructs (−1887/+50 and −370/+50)
and HRE-containing luciferase constructs (WT and Sp1/NF-YA double
mutant, described below) in vector control or Meis2-overexpressing
cells. Both TβRII promoter reporters and WT HRE reporter were
strongly induced by MS-275 that was abrogated by Meis2. Mutations
in Sp1 and NF-YA binding sites in HRE abolished HDI (MS-275)
inducibility (Figure 6A). MS-275 and TSA induces Sp1-dependent
transcription in ACC-LC-176 cells (Figure W2B). The Sp1-DNA
binding inhibitor mithramycin inhibited TβRII promoter activity in-
duced by MS-275 (Figure W2A), suggesting a role of Sp1 in HDI-
induced TβRII promoter activity. To determine the role of Sp1 and
NF-YA binding sites in HRE in HDI-mediated induction in TβRII
promoter activity, we generated reporter constructs with one copy of
WT HRE, mutated Sp1 binding site (HRE Sp1 mutant), mutated
NF-YA binding site (HRE NF-YA mutant), and mutated Sp1/NF-YA
binding sites. Mutation in either Sp1 or NF-YA site dramatically de-
creased the MS-275–induced luciferase activity when compared with
that of WT HRE reporter activity (Figure 6B). To test whether EGF
can affect MS-275–mediated TβRII reporter activation, we performed
transcription assays using above HRE reporter constructs as described
in Figure 6B. We observed that MS-275 treatment induced TβRII
reporter activity, whereas treatment with EGF significantly reduced
this activation (Figure 6C ). However, mutations in either Sp1 or
NF-YA or both SP1/NF-YA sites in the TβRII promoter dramatically
reduced reporter activities that were not affected significantly either by
MS-275 or EGF treatment (Figure 6C ), suggesting that the EGF-
mediated MEK/ERK signaling might be involved in regulating Sp1
and NF-YA–dependent transcriptional activity. Together, these results
suggest that both Sp1 and NF-YA sites are required for synergistic in-
crease in HRE reporter activity by HDIs, and Meis2 is involved in the
repression of HDI-inducible TβRII promoter activity.
AlthoughMeis2 was immunoprecipitated byHRE in the DAPA assay
(Figure 5C), we did not detect any DNA-protein complex formation
with Meis2 in EMSA (data not shown). To verify whether Meis2 was
coprecipitated with Sp1 and/or NF-YA in the DAPA experiment, we
testedwhetherMeis2 could interact with Sp1 and/orNF-YA in immuno-
precipitation and Western blot analyses. Tagged (HA or Flag) Meis2
was cotransfected with either Sp1-Flag or NF-YA-HA into 293T cells.
Meis2 was detected in the immune complexes of either Sp1 (Figure 6D,
left panel ) or NF-YA (right panel ), and in both cases, the amount of co-
immunoprecipitated Meis2 was not affected by TSA or MS-275 treat-
ment. Taken together, these results suggest that Meis2 may repress
transcription of TβRII through the interaction with Sp1 and NF-YA.
Discussion
The resistance to TGF-β–mediated tumor suppressor functions could
be caused by multiple ways involving both genetic and epigenetic
changes in TGF-β signaling molecules. However, mutations within
the coding sequence of the TβRII gene are rare in NSCLC. Mutations
in Smad2 and Smad4 genes have been found in 5% to 10% of lung
cancers [18,19]. In the present study, we have observed that HDIs
and not azacytidine can restore TβRII expression in lung cancer
VMRC-LCD and ACC-LC-176 cell lines lacking TβRII expression
but not in A549 cells having TβRII expression. These results suggest
that the cellular machinery in VMRC-LCD and ACC-LC-176 cell
lines recruit the HDAC activity to repress the transcription of TβRII,
and three structurally different HDIs restore this expression (Figure 2).
This is supported by the findings that HDIs induce TβRII promoter
activity and azacytidine cannot (Figure 4). As a functional consequence
of TβRII expression by HDIs, TGF-β signaling has been restored by
HDIs (Figure 1A). The dominant-negative type II receptor blocked
TGF-β–induced reporter activity in the presence of TSA, and constitu-
tively, active type I receptor activated the transcriptional responses in
the absence of TSA and TGF-β. Therefore, this cell line has intact
TGF-β/Smad signaling downstream of TβRII, and treatment of these
cells with HDI restores TGF-β signaling through reexpression of
TβRII. Similar restoration of TGF-β signaling by HDIs was observed
in ACC-LC-176 (data not shown). Restoration of TGF-β signaling in
VMRC-LCD cell line by HDI makes this cell line sensitive to TGF-β–
induced growth inhibition (Figure 1B), which is partially attenuated by
the specific inhibitor SB-431542 (Figure 1B, right panel ), suggesting
the restoration of endogenous TGF-β signaling by HDIs. Similarly,
TSA strongly decreases the colony-forming ability of VMRC-LCD
cells, which is partially blocked by SB-431542 (Figure 1C ). This
suggests that TGF-β signaling plays an important role in the anti-
tumor effects of HDIs particularly when TβRII expression is reduced
through HDAC inhibition. This is further supported by the in vivo
studies where stronger tumor regression by TSA using ACC-LC-176
or VMRC-LCD cells was observed when compared with A549 cells
(Figure 2D).
K-Ras is known to be mutated in around 30% of primary NSCLCs
[23]. The up-regulation or activation of EGFR in NSCLC (∼78%) is
associated with the activation of ERK1/2 [24]. Activation of Ras down-
regulates TβRII expression (Figure 3A) and activated Ras–induced
down-regulation of TβRII promoter activity is attenuated by HDIs
(data not shown), suggesting that histone deacetylation in activated
Ras cell line has a role in decreasing TβRII promoter activity. This is
supported by the fact that activated Ras– and EGF-induced down-
regulation of TβRII is inhibited by HDIs, and TβRII expression is re-
stored (Figure 3). This down-regulation of TβRII is blocked by MEK/
ERK pathway inhibitors (Figure 3C ). Together, activation of MEK/
ERK pathway bymutated Ras or EGF is involved in the down-regulation
of TβRII through the recruitment of HDAC activity.
Currently, there is no available literature about the interaction be-
tween oncogenic Ras and epigenetic regulation of TβRII expression in
lung cancer. However, a study showed that activation of Ras-MAPK
pathway by the expression of oncogenic Ras increases nuclear local-
ization of HDAC4 in C2C12 myoblast cells [25]. Furthermore,
ERK1/2 was found to be associated with HDAC4 in the nucleus
and phosphorylate it, suggesting that the chromatin-modifying enzyme
HDAC4 is a target of the Ras-MAPK signaling pathway [25]. Another
study demonstrated that reduced E-cadherin expression through his-
tone deacetylation plays an important role in developing resistance to
EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib. En-
hanced E-cadherin expression by exposure to HDI, MS-275, induces
sensitivity to gefitinib in resistant NSCLC cell lines [26]. This study
suggests a synergistic effect on growth inhibition and apoptosis from
sequential treatment with MS-275 and gefitinib. Thus, the sequential
combination of HDIs and EGFR tyrosine kinase inhibitors may pro-
vide a new therapeutic strategy for NSCLC patients. Although nothing
is known about the role of targeted therapies against EGFR, Ras, or
MAPK on TβRII expression in lung cancer, this study suggests that
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the inhibition of MAPK/ERK pathway may restore TGF-β–induced
tumor suppressor functions in NSCLC patients through the expression
of TβRII.
One of the most informative parts of this study is to identify fac-
tors that bind directly or indirectly to HRE in TβRII promoter region.
The identity of each protein has been confirmed by two or more peptide
sequences. Binding of Sp1 and NF-YA (Figure 5D, observed in proteo-
mics studies) was confirmed by EMSA and DAPA assays, which sup-
ports the specificity of binding of other proteins to the HRE sequence.
Sp1 and NF-YA binding to HRE is enhanced in response to HDIs,
suggesting that binding of these factors may be important in HDI-
mediated TβRII promoter induction. Proteomics studies have shown
the coprecipitation of Meis1 and Meis2 by HRE sequence. Meis1
and Meis2 can bind canonical TGAC-3′ site [27]. Because there is
TGGC-3′ sequence within HRE, it is tempting to hypothesize that
they bind to this sequence. However, we do not observe such binding
in the EMSA with HRE as a probe (data not shown). Interestingly, our
data indicate that Meis2 interacts with Sp1 and NF-YA, suggesting that
Meis2 may be coprecipitated through this protein-protein interaction.
In an attempt to understand the functional outcome of this interaction,
we have observed that Meis2 represses HDI-induced TβRII tran-
scription through the HRE. Sp1 [28] and/or NF-YA [29] can recruit
HDAC to the promoter and causes chromatin condensation leading to
transcriptional repression. It is possible that Meis2 may help to recruit
HDAC activity on to the TβRII promoter through the interaction with
Sp1 and NF-YA, thus leading to TβRII down-regulation. In addition
to Meis proteins, other TALE homeobox proteins like PBX2/3 and
pKnox1 are also coprecipitated with WT HRE. The N-terminal do-
main of Pbx interacts with either Meis or pKnox forming a heterodimer
that cooperatively binds to the TGAT-TGAC sequence [28], where
Pbx proteins bind to the TGAT motif and Meis or pKnox proteins
bind to the TGAC element. It is possible that Pbx-Meis or Pbx-pKnox
complexes bind to the TGAT-TGGC element on the TβRII promoter
that overlaps with the NF-YA binding element, inverted CCAAT box.
These complexes may recruit corepressors or HDACs and repress tran-
scription of TβRII, which is consistent with a previous study [30]. The
HDIs could activate transcription through the activation of coactivators
or the replacement of HDAC activity. Another scenario for the regula-
tion of TβRII promoter activity could be due to the competition be-
tween the Pbx-Meis/pKnox complex and the NF-YA complex for
binding the overlapping sequence. Future studies will address these
different levels of transcriptional complexity in regulating TβRII ex-
pression in lung cancer.
TGF-β signaling plays an important role in the development of most
human solid tumors in advanced stages, and numerous studies support
targeting TGF-β signaling as therapeutic strategy for cancer treatment.
Although, to date, several approaches have been developed for blocking
TGF-β signaling pathways and several drugs have been developed that
are either in nonclinical or in early stages of clinical investigation, the
small-molecule inhibitors of TGF-β signaling could be very useful for
the development of therapeutic strategies for treatment of human
cancers [18,31]. The most desirable approach for developing a new
therapeutic strategy by targeting TGF-β signaling would be to retain
TGF-β–induced tumor-suppressor functions but to block TGF-β–
mediated prooncogenic signaling in advanced invasive and metastatic
cancers. Most TGF-β signaling small-molecule inhibitors target to
the kinase domain of TβRI, which differs considerably from that of
TβRII, thus giving specificity for inhibition of TβRI versus TβRII sig-
naling. The main strategy for inhibition of the TGF-β signaling path-
way is to include compounds that interfere with the binding of TGF-β
to its receptors, drugs that block intracellular signaling, and antisense
oligonucleotides. Strategies that block catalytic activity of TβRI in-
cluding the small molecules such as SB-431542 and SB-505124
(GlaxoSmithKline), SD-093 and SD-208 (Scios), and LY580276 (Lilly
Research Laboratories), act as competitive inhibitors for the ATP-
binding site of TβRI kinase [32]. Studies with pan-TGF-β–neutralizing
antibodies and soluble TβRII-Fc fusion protein suggest that suppres-
sion of tumor progression by blocking TGF-β signaling network may
provide an attractive target for therapeutic intervention [33,34]. Studies
with soluble Fc:TβRII, used either as an injectable drug [34] or when
stably expressed as a transgene [35], antagonize TGF-β signaling and
reduce mammary tumor metastasis to the lung. Thus, TGF-β receptor
kinase inhibitors might be useful in developing therapeutic strategies
for human cancers. However, the main challenge will involve identify-
ing the appropriate patients for therapy to ensure that targeted tumors
are refractory to TGF-β–induced tumor suppressor functions but re-
sponsive to tumor-promoting effects of TGF-β.
In summary, our study has demonstrated, for the first time, the
identification of a number of proteins/factors involved in the regula-
tion of TβRII in lung cancer cell lines and how Meis proteins may be
involved in the loss of TβRII expression. This study provides an impor-
tant clue about how activation of MAPK/ERK pathway plays a role in
the down-regulation of TβRII through histone deacetylation. In addi-
tion, TGF-β–induced tumor suppressor function is restored in TGF-β–
resistant lung cancer cells by HDIs. Because most lung tumors are
resistant to TGF-β because of the loss of TβRII through histone
deacetylation, HDAC inhibitors may have potential for therapeutic
intervention either alone or in combination with other agents.
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Figure W3. Sequences of primer sets used to generate proximal TβRII promoter constructs. The oligonucleotides corresponding to the
TβRII promoter −115/−65 sequence (WT) or the mutant oligos (mutated Sp1, mutated NF-YA or double mutant binding sites) were
annealed and inserted into the Kpn1/Xho1 sites of pGL3 vector containing the MLP sequence. The consensus Sp1 binding site and
NF-YA binding site are shown as bold. The mutant oligonucleotide sequences are underlined and shown by italic letters.
Figure W1. Overexpression of Meis2 in stable clones. pCDNA3-
Meis2-HA plasmid was transfected into ACC-LC-176 cells, selected
in G418 (600 μg/ml) for 3 weeks, and then individual clones were
isolated. The expression of Meis2-HA protein was verified by
Western blot analysis with anti-HA antibody. Clones that expressed
higher levels of exogenous Meis2 were maintained in culture with
200 μg/ml G418.
Figure W2. MS-275 induces Sp1-dependent transcription in ACC-
LC-176 cells. Transcription assay: ACC-LC-176 cells were transiently
transfected with TβRII 5′-promoter constructs (A) and Sp1-Luc
construct (B) that contains three copies of consensus Sp1 binding
sites. Transfected cells were treated with MS-275 in the presence or
absence of mithramycin (150 nM) as well as both TSA and MS-275
as indicated, and the relative luciferase activities are shown. *P <
.05 compared with the corresponding control. **P< .05 when com-
pared between the corresponding treatment points. ΔP < .05 com-
pared with the MS-275 treatment dose. ΔΔP < .05 compared with
the TSA treatment dose.
